Full text is available at the source.
Abstract
A consensus position on the optimal use of incretin receptor agonists was developed following a meeting on December 3, 2025.
- The meeting addressed safety concerns regarding tirzepatide and semaglutide in patients with overweight and obesity.
- Personalized approaches to using these medications were discussed to enhance treatment effectiveness.
- The expert working group aimed to establish guidelines for real-world clinical practice involving these drugs.
Simplified